Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.35
APRI's Cash to Debt is ranked higher than
61% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. APRI: 3.35 )
Ranked among companies with meaningful Cash to Debt only.
APRI' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 3.35

Equity to Asset 0.09
APRI's Equity to Asset is ranked lower than
64% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.43 vs. APRI: 0.09 )
Ranked among companies with meaningful Equity to Asset only.
APRI' s 10-Year Equity to Asset Range
Min: -0.04   Max: 0.87
Current: 0.09

-0.04
0.87
F-Score: 4
Z-Score: -21.64
M-Score: 2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -258.25
APRI's Operating margin (%) is ranked lower than
72% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. APRI: -258.25 )
Ranked among companies with meaningful Operating margin (%) only.
APRI' s 10-Year Operating margin (%) Range
Min: -25298.53   Max: -86.86
Current: -258.25

-25298.53
-86.86
Net-margin (%) -256.17
APRI's Net-margin (%) is ranked lower than
72% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. APRI: -256.17 )
Ranked among companies with meaningful Net-margin (%) only.
APRI' s 10-Year Net-margin (%) Range
Min: -23786.76   Max: -83.71
Current: -256.17

-23786.76
-83.71
ROE (%) -343.26
APRI's ROE (%) is ranked lower than
80% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. APRI: -343.26 )
Ranked among companies with meaningful ROE (%) only.
APRI' s 10-Year ROE (%) Range
Min: -1512.53   Max: -38.69
Current: -343.26

-1512.53
-38.69
ROA (%) -125.28
APRI's ROA (%) is ranked lower than
82% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. APRI: -125.28 )
Ranked among companies with meaningful ROA (%) only.
APRI' s 10-Year ROA (%) Range
Min: -217.31   Max: -37.07
Current: -125.28

-217.31
-37.07
ROC (Joel Greenblatt) (%) -1839.46
APRI's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. APRI: -1839.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2232.26   Max: -68.6
Current: -1839.46

-2232.26
-68.6
Revenue Growth (3Y)(%) 4.80
APRI's Revenue Growth (3Y)(%) is ranked higher than
66% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.40 vs. APRI: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 105.1
Current: 4.8

0
105.1
EBITDA Growth (3Y)(%) -12.80
APRI's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -31.90 vs. APRI: -12.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APRI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 49.9
Current: -12.8

0
49.9
EPS Growth (3Y)(%) -14.10
APRI's EPS Growth (3Y)(%) is ranked higher than
63% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -53.60 vs. APRI: -14.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.3   Max: 78.2
Current: -14.1

-44.3
78.2
» APRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

APRI Guru Trades in

APRI Guru Trades in

Q4 2014

APRI Guru Trades in Q4 2014

Jim Simons 53,629 sh (New)
» More
Q1 2015

APRI Guru Trades in Q1 2015

Charles Brandes 53,500 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with APRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 55.60
APRI's P/B is ranked lower than
99% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. APRI: 55.60 )
Ranked among companies with meaningful P/B only.
APRI' s 10-Year P/B Range
Min: 1.43   Max: 127.5
Current: 55.6

1.43
127.5
P/S 7.20
APRI's P/S is ranked lower than
89% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. APRI: 7.20 )
Ranked among companies with meaningful P/S only.
APRI' s 10-Year P/S Range
Min: 0.78   Max: 1380
Current: 7.2

0.78
1380
Current Ratio 2.52
APRI's Current Ratio is ranked higher than
68% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. APRI: 2.52 )
Ranked among companies with meaningful Current Ratio only.
APRI' s 10-Year Current Ratio Range
Min: 0.12   Max: 85.68
Current: 2.52

0.12
85.68
Quick Ratio 2.49
APRI's Quick Ratio is ranked higher than
74% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. APRI: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
APRI' s 10-Year Quick Ratio Range
Min: 0.12   Max: 85.68
Current: 2.49

0.12
85.68
Days Inventory 98.56
APRI's Days Inventory is ranked higher than
69% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 151.00 vs. APRI: 98.56 )
Ranked among companies with meaningful Days Inventory only.
APRI' s 10-Year Days Inventory Range
Min: 23.31   Max: 121.47
Current: 98.56

23.31
121.47
Days Sales Outstanding 19.24
APRI's Days Sales Outstanding is ranked higher than
93% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.78 vs. APRI: 19.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
APRI' s 10-Year Days Sales Outstanding Range
Min: 1.87   Max: 488.31
Current: 19.24

1.87
488.31

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 54.70
APRI's Price/Tangible Book is ranked lower than
100% of the 824 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.50 vs. APRI: 54.70 )
Ranked among companies with meaningful Price/Tangible Book only.
APRI' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 90.15
Current: 54.7

2.1
90.15
Price/Median PS Value 0.40
APRI's Price/Median PS Value is ranked higher than
97% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. APRI: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
APRI' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 151.6
Current: 0.4

0.09
151.6
Earnings Yield (Greenblatt) -34.80
APRI's Earnings Yield (Greenblatt) is ranked lower than
88% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. APRI: -34.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
APRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -44.4   Max: 0
Current: -34.8

-44.4
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:NXEN.Germany,
Apricus Biosciences Inc was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with our NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.
» More Articles for APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... May 28 2015
4:02 pm Apricus Biosciences announces launch of its topical treatment for Erectile Dysfunction in... May 28 2015
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... May 28 2015
APRICUS BIOSCIENCES, INC. Financials May 20 2015
10-Q for Apricus Biosciences, Inc. May 14 2015
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 14 2015
Apricus Biosciences Inc Earnings Call scheduled for 8:30 am ET today May 11 2015
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2015
Apricus reports 1Q loss May 11 2015
Apricus reports 1Q loss May 11 2015
Q1 2015 Apricus Biosciences Inc Earnings Release - Time Not Supplied May 11 2015
Apricus Biosciences Provides Corporate Update and First Quarter 2015 Financial Results May 11 2015
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... May 06 2015
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in... May 06 2015
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... May 05 2015
10-K for Apricus Biosciences, Inc. May 04 2015
Apricus Biosciences Announces Corporate Update and First Quarter 2015 Financial Results Conference... May 04 2015
Apricus Biosciences Announces Corporate Update and First Quarter 2015 Financial Results Conference... May 04 2015
Apricus Biosciences to Present at Two Investor Conferences in May Apr 28 2015
Apricus Biosciences, Inc. to Present at Taglich Brothers 12th Annual Investment Conference Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK